该批准得到了随机、双盲、安慰剂对照3期EoE KIDS研究(ClinicalTrials.gov 标识符:NCT04394351)的数据支持,该研究评估了dupilumab在患者中的疗效和安全性1至11岁且具有活跃EoE,该试验分为两部分(A部分和B部分)。 尽管在筛选前或筛选期间接...
该批准得到了随机、双盲、安慰剂对照3期EoE KIDS研究(ClinicalTrials.gov 标识符:NCT04394351)的数据支持,该研究评估了dupilumab在患者中的疗效和安全性1至11岁且具有活跃EoE,该试验分为两部分(A部分和B部分)。 尽管在筛选前或筛选期间接受了质子泵抑制剂治疗并且有EoE体征和症状史,但符合条件的患者在每个高倍视野 ...
目前尚不清楚 DUPIXENT 对 12 岁以下患有慢性鼻窦炎伴鼻息肉的儿童是否安全有效。 (4) 用于治疗体重至少 33 磅(15 公斤)的嗜酸细胞性食管炎 (EoE) 成人和 1 岁及以上儿童。目前尚不清楚 DUPIXENT 对 1 岁以下或体重低于 33 磅(15 公斤)的嗜酸细胞性食管炎儿童是否安全有效。 (5) 用于治疗成人结节性痒疹 ...
In clinical trials in over 2,100 adults with uncontrolled moderate-to-severe eczema (atopic dermatitis), clearer skin was seen in 16 weeks of treatment with Dupixent. Clear or almost clear skin was reported in 37% of patients taking Dupixent compared to 9% of those not using the drug, a ...
The safety and effectiveness in adults and pediatric patients were similar [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY and Clinical Studies]. The safety and effectiveness of DUPIXENT for the treatment of EoE in pediatric patients less than 12 years of age and weighing less than 40 kg have not ...
Dupilumab Development ProgramDupilumab is being jointly developed byRegeneronand Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type ...
In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including pediatric EoE, chronic spontaneous urticaria, chronic pruritus of unknown origin, chronic ...
In addition to the currently approved indications, Regeneron andSanofiare studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including pediatric EoE, chronic spontaneous urticaria, chronic pruritus of unknown origin, chro...
Print Clinical researchPhase IIIBest Places to Work Regeneron Pharmaceuticals, Inc.Sanofi (France) MORE ON THIS TOPIC Weight Loss ‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss November 26, 2024...
The safety and effectiveness in adults and pediatric patients were similar [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY and Clinical Studies]. The safety and effectiveness of DUPIXENT for the treatment of EoE in pediatric patients less than 12 years of age and weighing less than 40 kg have not ...